Pargluva Development May Be Terminated By Bristol, Merck
This article was originally published in The Pink Sheet Daily
Executive Summary
Regulatory approval and commercial success of the investigational type 2 diabetes drug will require additional clinical trials that could take up to five years to complete, Bristol says.
You may also be interested in...
Merck Research Appointment Reflects Firm's Emphasis On Diabetes, Obesity
Academic Rossetti will have responsibility over scientific direction of Merck's pipeline in the therapeutic areas as VP and franchise head.
Merck Research Appointment Reflects Firm's Emphasis On Diabetes, Obesity
Academic Rossetti will have responsibility over scientific direction of Merck's pipeline in the therapeutic areas as VP and franchise head.
Bristol Joins The Ranks: Firm Bags Pargluva Development
Merck, AstraZeneca and Roche have already stepped out of the dual PPAR development arena.